A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer-Reference-Cited by-同舟云学术

A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer

Published:2012-06 Issue:3 Volume:12 Page:167-174
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Roché Henri,De Benedictis Elena,Cottura Ewa,Govi Silvia,Dalenc Florence,Locatelli Alberta,Deslandres Marion,Zambetti Milvia,Gladieff Laurence,Messina Marianne,Gianni Luca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer;Sherrill;Br J Cancer,2008

2. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules;Bode;Biochemistry,2002

3. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors;Rivera;Oncologist,2008

4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent;Lee;Cancer Chemother Pharmacol,2008

5. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer;Low;J Clin Oncol,2005

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio;2019-08-01

2. Olive leaf extract containing oleuropein modulates the cytotoxic effect of epirubicin on breast cancer cells depending on the cell line;Turkish Journal of Biochemistry;2016-01-01

3. Development of other microtubule-stabilizer families;Anti-Cancer Drugs;2014-06

4. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma;Asian Pacific Journal of Cancer Prevention;2014-04-30

5. From Bacteria to Antineoplastic: Epothilones A Successful History;Anti-Cancer Agents in Medicinal Chemistry;2013-07-01